Biomedical subjects

V Linasmita

Publications and source records attributed to V Linasmita.

36 records · Page 2Linked to original sources

PubMed1993

Trends in uterine curettage among women under 30 with abnormal uterine bleeding at Ramathibodi Hospital.

This study represents the follow-up on number and trends of uterine curettage in women aged under 30 with menstrual disturbances in this institution. The total number of patients under 30 seen at the gynecological outpatient service with AUB decreased over the year studied, from January 1, 1987 to December 31, 1990. The trends in uterine curettage among this group of patients have also decreased, 125 (16.6%) cases in 1987, 101 (17.2%) cases in 1988, 75 (14.2%) cases in 1989 and 72 (14.1%) cases in 1990. The majority of patients had no significant pathology on the curetting tissues. Endometrial hyperplasia was found in 8 cases (4.6%). There was no case of endometrial carcinoma.

Adult↗

PubMed1993

Hospital charge of gynecological in-patients at Ramathibodi Hospital.

There have been few studies of hospital charge done in Thailand and that led us to be aware of health economics. In this cross sectional study, 182 gynecological in-patients admitted between July 1 and 31, 1990 were recruited. Mean hospital charge was 3,258.50 baht. The patients's employers bore the main financial burden (48%). The hospital bore 9 per cent of this total financial burden, and the rest (44%) was self paid. The amount of hospital charge may depend on some factors. Further study of this subject should be conducted.

Adolescent↗

PubMed1991

Obstetric hysterectomy: Ramathibodi's experience 1969-1987.

Obstetric hysterectomy was performed on 121 women at Ramathibodi Hospital, Bangkok, between 1969 and 1987, an incidence of 1:875 deliveries. Of 88 women whose records were available, 91% had emergency hysterectomy, with uterine atony as the most common indication (32.5%), followed by placenta accreta (26.2%), uterine rupture (10.0%), extension of cervical tear to the lower uterine segment (8.7%), broad ligament hematoma (6.2%) and placenta previa (5.0%). The intraoperative and postoperative problems included febrile morbidity (52%), intraoperative hypotension (41%), and disseminated intravascular coagulation (5.7%). Late complications included Sheehan's syndrome (3.4%), post-transfusion hepatitis (2.3%), hematoma (2.3%) and wound infection (2.3%).

Adolescent↗

PubMed1990

The risk factors in the development of persistent trophoblastic disease following hydatidiform mole.

Hydatidiform mole (HM) is not uncommon in our country. Its dangerous sequalae is the fatal persistent trophoblastic disease (PTD). The prognostic risk factors for the development of PTD were analyzed in 108 cases of HM treated in Ramathibodi Hospital from 1978 to 1986. Statistical univariate analysis was by calculation of relative risk (RR) and chi-square test. The incidence of PTD was 27.8 per cent. The significant risk factors were the presence of theca-lutein cyst, gestational age of less than 16 weeks, "large for date" uterus, and patients' age of 40 years or more. Their RR were 4.25, 3.11, 3.00 and 2.68 respectively. These findings were comparable with previous reports. The use of prophylactic chemotherapy in patients with these risk factors was suggested.

Adolescent↗

PubMed1990

Uterine sarcomas at Ramathibodi Hospital (1969-1986).

Uterine sarcoma is a rare gynecological malignancy. This retrospective study covered a period of 18 years and during that time 15 cases of uterine sarcoma were treated in Ramathibodi Hospital. It represented an incidence of 6 per 10,000 gynecological admissions. There were 9 leiomyosarcomas, 3 endometrial stromal sarcomas, 2 mixed mullerian sarcomas, and one rhabdomyosarcoma. The average age of the patients was 45.67 years, 3 under 40 and five after menopause. The mean parity was 4. The most common presenting symptoms were vaginal bleeding and abdominal mass. The diagnostic curettage was positive in only 2 out of 7 cases. All were treated by hysterectomy and bilateral salpingo-oophorectomy. Two out of 4 cases who received adjuvant radiotherapy or chemotherapy were still-alive at 1 and 3 year follow-up. The crude survival rate was 40 per cent.

Adult↗

PubMed1990

Assessment of endocervical curettage in colposcopy.

Colposcopy has become an accepted diagnostic procedure in the management of patients with abnormal cervical cytology. To assess the value of the endocervical curettage in colposcopy, a retrospective review of 125 cases who had the procedure done during the 20-month period (January 1986-August 1988) was carried out. The ECC were positive in 3 out of 57 (5.3%) patients with satisfactory examination and 24 out of 68 (35.3%) patients with unsatisfactory examination. In all 27 cases, there was insufficient tissue to make a diagnosis of invasive carcinoma. Of the 125 patients studied seventy-two (29 in the satisfactory group and 43 in the unsatisfactory group) underwent conization and/or hysterectomy. Endocervical curettage did not eliminate the need for cone biopsy in all cases of unsatisfactory colposcopy. The tissue diagnosis on ECC did not increase the diagnostic accuracy derived from the colposcopic directed biopsies in either group. There were 20 cases of invasive carcinoma (13 MIC, 7 invasive) in this study, the ECC were positive in 9. We concluded that the ECC has limited value in colposcopy.

Colposcopy↗

PubMed1990

Survival of patients with stage I epithelial ovarian carcinoma, 1981-1985 at Ramathibodi Hospital.

Thirty-one patients with stage I epithelial ovarian carcinoma were treated during 1981 and 1985. Fourteen cases were stage Ia, two stage Ib and fifteen stage Ic. Twenty-eight cases had at least a TAH with BSO. Postoperatively, twenty-one patients received melphalan as adjuvant chemotherapy (mean of 11 courses). There were 8 patients who received no adjunctive therapy. One patient had radiation treatment and the remaining one received hormonal treatment. Eighty-seven per cent (27 out of 31) of tumors were of borderline type or well differentiated, four were moderately well differentiated. Poorly differentiated tumor was not observed in our series. The follow-up (31 patients) ranged from 0-82 months with a median of 52 months. The overall 5-year survival was 95.4 per cent. There was one reported death whose tumor was stage Ic grade 1 and who had received melphalan postoperatively. No serious adverse effects were noted among patients who received melphalan.

Adult↗

PubMed1988